Development of SARS-CoV-2 entry antivirals
Cell Insight,
Год журнала:
2024,
Номер
3(1), С. 100144 - 100144
Опубликована: Янв. 30, 2024
The
global
outbreak
of
the
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
threatened
human
health
and
public
safety.
development
anti-SARS-CoV-2
therapies
have
been
essential
to
curb
spread
SARS-CoV-2.
Particularly,
antivirals
targeting
viral
entry
become
an
attractive
target
for
therapies.
In
this
review,
we
elucidate
mechanism
SARS-CoV-2
summarize
antiviral
inhibitors
entry.
Moreover,
speculate
upon
future
directions
toward
more
potent
This
study
is
expected
provide
novel
insights
efficient
discovery
promising
candidate
drugs
against
SARS-CoV-2,
contribute
broad-spectrum
anti-coronavirus
drugs.
Язык: Английский
A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors
Current Issues in Molecular Biology,
Год журнала:
2023,
Номер
45(1), С. 400 - 433
Опубликована: Янв. 4, 2023
SARS-CoV-2
(severe
acute
respiratory
syndrome)
is
highly
infectious
and
causes
severe
distress
syndrome
(SARD),
immune
suppression,
multi-organ
failure.
For
SARS-CoV-2,
only
supportive
treatment
options
are
available,
such
as
oxygen
therapy,
ventilator
support,
antibiotics
for
secondary
infections,
mineral
fluid
treatment,
a
significant
subset
of
repurposed
effective
drugs.
Viral
targeted
inhibitors
the
most
suitable
molecules,
ACE2
(angiotensin-converting
enzyme-2)
RBD
(receptor-binding
domain)
protein-based
inhibitors,
host
proteases,
viral
proteases
3CLpro
(3C-like
proteinase)
PLpro
(papain-like
protease),
replicative
enzymes,
attachment
to
receptor
TMPRSS2
(transmembrane
serine
proteinase
2),
HR1
(Heptad
Repeat
1)–HR2
2)
interaction
at
S2
protein
coronavirus,
etc.
Targeting
cathepsin
L
proteinase,
peptide
analogues,
monoclonal
antibodies,
chimaeras
interferes
with
spike
protein’s
ability
fuse
membrane.
Even
tremendous
progress
made,
creating
drugs
remains
difficult.
To
develop
COVID-19
alternatives,
clinical
studies
examining
variety
therapy
categories,
including
antivirals,
cell-based
diagnostic
medicines,
more.
In
this
article,
we
discuss
recent
updates
on
infection,
characteristics,
diagnosis,
immunopathology,
new
emergence
variant,
various
approaches
drug
development
options.
The
therapies
has
been
complicated
by
global
occurrence
many
mutations.
Discussion
manuscript
will
provide
insight
into
pathophysiology
development.
Язык: Английский
Inflammation as Prognostic Hallmark of Clinical Outcome in Patients with SARS-CoV-2 Infection
Life,
Год журнала:
2023,
Номер
13(2), С. 322 - 322
Опубликована: Янв. 23, 2023
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
is
often
characterized
by
a
life-threatening
interstitial
pneumonia
requiring
hospitalization.
The
aim
of
this
retrospective
cohort
study
to
identify
hallmarks
in-hospital
mortality
in
patients
affected
Coronavirus
Disease
19
(COVID-19).
A
total
150
admitted
for
COVID-19
from
March
June
2021
“F.
Perinei”
Murgia
Hospital
Altamura,
Italy,
were
divided
into
survivors
(n
=
100)
and
non-survivors
groups
50).
Blood
counts,
inflammation-related
biomarkers
lymphocyte
subsets
analyzed
two
the
first
24
h
after
admission
compared
Student’s
t-test.
multivariable
logistic
analysis
was
performed
independent
risk
factors
associated
with
mortality.
Total
count
CD3+
CD4+
CD8+
T
significantly
lower
non-survivors.
Serum
levels
interleukin-6
(IL-6),
lactate
dehydrogenase
(LDH),
C-reactive
protein
(CRP)
procalcitonin
(PCT)
higher
Age
>
65
years
presence
comorbidities
identified
as
mortality,
while
IL-6
LDH
showed
borderline
significance.
According
our
results,
markers
inflammation
lymphocytopenia
predict
COVID-19.
Язык: Английский